Cover Image
市場調查報告書

復發性急性骨髓性白血病:開發平台分析

Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 305181
出版日期 內容資訊 英文 442 Pages
訂單完成後即時交付
價格
Back to Top
復發性急性骨髓性白血病:開發平台分析 Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 442 Pages
簡介

所謂復發型急性骨髓性白血病(AML)症狀有發紫、牙齦腫、肛門周圍疼痛、食慾不振、骨頭及關節的疼痛/不協調感等。

本報告提供復發性急性骨髓性白血病的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

復發性急性骨髓性白血病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

復發性急性骨髓性白血病:企業開發中的治療藥

復發性急性骨髓性白血病:大學/機關研究中的治療藥

復發性急性骨髓性白血病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

復發性急性骨髓性白血病:企業開發中的產品

復發性急性骨髓性白血病:大學/機關研究中的產品

復發性急性骨髓性白血病的治療藥開發作的企業

  • 4SC AG
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • BioLineRx, Ltd.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Cornerstone Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
  • 第一三共
  • Eisai
  • EpiZyme, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FORMA Therapeutics, Inc.
  • Fujifilm
  • GlaxoSmithKline Plc
  • Igenica Biotherapeutics, Inc.
  • Incyte Corporation
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • JW Pharmaceutical Corporation
  • Karyopharm Therapeutics, Inc.
  • Kyowa Hakko Kirin
  • Les Laboratoires Servier SAS
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • NantKwest, Inc.
  • Novartis AG
  • 大塚集團
  • Oxford BioTherapeutics Ltd
  • Pharma Mar, S.A.
  • Polaris Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Sunesis Pharmaceuticals, Inc.
  • Synta Pharmaceuticals Corp.
  • TaiGen Biotechnology Co., Ltd.
  • Tolero Pharmaceuticals, Inc.
  • Verastem, Inc.

復發性急性骨髓性白血病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 4SC-202
  • AG-120
  • alvocidib hydrochloride
  • AMG-232
  • aNK Program
  • AT-9283
  • BI-836858
  • binimetinib
  • BL-8040
  • bortezomib
  • brentuximab vedotin
  • burixafor
  • cabozantinib s-malate
  • cafusertib hydrochloride
  • CB-839
  • CC-90007
  • 復發性急性骨髓性白血病CD123 標的細胞療法
  • 復發性急性骨髓性白血病CD33 標的細胞療法
  • 造血器惡性腫瘤腫瘤相關抗原標的細胞療法
  • 適合腫瘤學T-1/NY-ESO-1/PRAME/Survivin標的細胞療法
  • CPI-613
  • crenolanib besylate
  • CWP-291
  • DS-3032
  • E-6201
  • elesclomol
  • eltrombopag olamine
  • erlotinib hydrochloride
  • FF-10501
  • ficlatuzumab
  • FLX-925
  • FT-1101
  • gilteritinib fumarate
  • GO-2032c
  • GSK-2879552
  • GSK-525762
  • Hu8F4
  • huCART19
  • IGN-523
  • ilorasertib
  • imatinib mesylate
  • indisulam
  • Iomab-B
  • KHK-2823
  • lenalidomide
  • lirilumab
  • lurbinectedin
  • MGD-006
  • MK-2206
  • napabucasin
  • OPB-51602
  • Oshadi D + Oshadi R
  • OX-001
  • pegargiminase
  • PIM-447
  • pinometostat
  • quizartinib dihydrochloride
  • RG-7775
  • ruxolitinib phosphate
  • S-055746
  • selinexor
  • selumetinib sulfate
  • TAK-659
  • TEN-010
  • tigecycline
  • tosedostat
  • trametinib dimethyl sulfoxide
  • trametinib dimethyl sulfoxide + uprosertib
  • ulocuplumab
  • venetoclax
  • vorinostat
  • vosaroxin
  • VS-4718

復發性急性骨髓性白血病:最近的開發平台趨勢

復發性急性骨髓性白血病:暫停中的計劃

復發性急性骨髓性白血病:開發中止的產品

復發性急性骨髓性白血病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8605IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Relapsed Acute Myeloid Leukemia (Oncology) pipeline landscape.

Return of acute myeloid leukemia (AML) cells in the marrow and a decrease in normal blood cells after remission is called a relapsed acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment includes chemotherapy with the same or different drugs used previously during treatment.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 35, 35, 1, 3 and 1 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 2 molecules, respectively for Relapsed Acute Myeloid Leukemia.

Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Relapsed Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Relapsed Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Relapsed Acute Myeloid Leukemia Overview
  • Therapeutics Development
  • Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies
  • Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes
  • Relapsed Acute Myeloid Leukemia - Pipeline Products Glance
  • Relapsed Acute Myeloid Leukemia - Products under Development by Companies
  • Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes
  • Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development
  • Relapsed Acute Myeloid Leukemia - Therapeutics Assessment
  • Drug Profiles
  • Relapsed Acute Myeloid Leukemia - Dormant Projects
  • Relapsed Acute Myeloid Leukemia - Discontinued Products
  • Relapsed Acute Myeloid Leukemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Relapsed Acute Myeloid Leukemia, H2 2016
  • Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by 4SC AG, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by AbbVie Inc, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by ADC Therapeutics Sarl, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Aeglea BioTherapeutics, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Aileron Therapeutics, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Amgen Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by AstraZeneca Plc, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Bio-Cancer Treatment International Limited, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by BioLineRx, Ltd., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by BioSight Ltd., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Boston Biomedical, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Eli Lilly and Company, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by FLX Bio, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics Inc, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by GlycoMimetics, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by NantKwest, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Pfizer Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016
  • Relapsed Acute Myeloid Leukemia - Pipeline by ZIOPHARM Oncology, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Relapsed Acute Myeloid Leukemia - Dormant Projects, H2 2016
  • Relapsed Acute Myeloid Leukemia - Dormant Projects (Contd..1), H2 2016
  • Relapsed Acute Myeloid Leukemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Relapsed Acute Myeloid Leukemia, H2 2016
  • Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top